Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4700421 | 0.91 | CHRM2 (0.50) | CPB2CHRM2CHRM4CHRM5CHRM1 | |
| Trifluoroacetic Acid SCHEMBL31657036 | 0.82 | MEN1 (0.52) | CPB2 | |
| Trifluoroacetic Acid SCHEMBL29682080 | 0.82 | MEN1 (0.52) | CPB2 | |
| Diaminooctane SCHEMBL31657050 | 0.82 | MEN1 (0.52) | CPB2 | |
| Trifluoroacetic Acid SCHEMBL31657055 | 0.82 | MEN1 (0.52) | CPB2 | |
| Trifluoroacetic Acid SCHEMBL3749229 | 0.81 | SMN1; SMN2 (0.67) | PAOX | |
| SCHEMBL1614358 | 0.79 | ALOX15 (0.58) | SIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL6490887 | 0.79 | HRH4 (0.50) | CPB2 | |
| SCHEMBL1614410 | 0.79 | ALOX15 (0.58) | SIGMAR1 | |
| SCHEMBL1614431 | 0.79 | ALOX15 (0.58) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1968969-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007071396-A2 | PYRAZINOYLGUANIDINE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | CPB2 3834/4885CHRM2 19/4885CHRM4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.